Updated Viloxazine Pharmacology: Experiments Establish Norepinephrine Transporter Occupancy and Serotonin 5-HT_2C, 5-HT_2B, and 5-HT₇ Receptor Binding at Therapeutically Relevant Concentrations

CONCLUSIONS: These results validate previous experiments showing that viloxazine, in addition to displaying high NET occupancy, acts as a partial agonist at 5-HT(2C) receptors and an antagonist at 5-HT(2B) and 5-HT(7) receptors at clinically relevant concentrations for ADHD treatment. Therefore, both NET inhibition and serotonin receptor activity may contribute to viloxazine’s clinical efficacy. These findings are contributing to a renewed understanding of viloxazine’s pharmacodynamic profile…

via https://pubmed.ncbi.nlm.nih.gov/41931242/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1lqZ3NPYysePVKsoyz66mDSgu4veDGJwnUBS47TBQPoOuNZY5J&fc=None&ff=20260413011005&v=2.19.0.post6+133c1fe